 Recent evidence suggests that patients with concomitant chronic HCV infection and NASH or significant hepatic steatosis 33 respond less well to standard antiviral therapy. As previously noted, up to 10 of patients with chronic HCV infection will have concomitant NASH and an even greater percentage will have associated hepatic steatosis. No prospective studies to date have evaluated the sustained viral response rates to standard antiviral therapy in this group of patients who were previously treated with a medication to eliminate or improve the underlying NASH andor hepatic steatosis. 